Autologous Stem Cell Transplant — High-Dose Therapy Rescue

An autologous stem cell transplant involves collecting a patient's own haematopoietic stem cells before administering high-dose chemotherapy, with or without total body irradiation. These blood-forming cells are gathered from peripheral blood through a process called apheresis and then cryopreserved. The primary goal of the high-dose therapy is to eradicate as many malignant cells as possible, even though this completely wipes out the bone marrow's blood-producing capability.

Once the intensive conditioning therapy clears from the body, the frozen stem cells are thawed and infused back into the bloodstream via a central venous catheter. The infused stem cells travel through circulation and settle into the bone marrow spaces in a biological process termed engraftment. Over two to three weeks, they multiply and regenerate normal red cells, white cells, and platelets.

This procedure offers a potentially durable remission or deep disease control for specific haematological cancers that have returned or remain aggressive. Because it uses your own cells, there is no risk of graft-versus-host disease, and donor matching is unnecessary. However, the period before engraftment leaves you severely vulnerable to infections, anaemia, and bleeding. Understanding the preparation, hospitalisation, and recovery phases helps you and your caregivers anticipate supportive care needs, such as transfusions, isolation, and antibiotic prophylaxis.

Before transplantation, extensive testing ensures your body can tolerate the process. This includes bone marrow biopsies to check disease status, PET or CT scans, echocardiograms or MUGA scans for cardiac function, and pulmonary function tests. CD34 biomarker analysis monitors peripheral blood to ensure adequate numbers of mobilised stem cells are circulating before apheresis collection begins.

Autologous stem cell transplants are most frequently used to treat multiple myeloma, Hodgkin lymphoma, and various subtypes of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma. They are also occasionally utilised in certain solid tumours, such as relapsed testicular germ cell tumours and high-risk neuroblastoma in children.

This procedure is a consolidating treatment delivered after standard induction therapy has already minimised the cancer burden. It entails conditioning regimens using high-dose chemotherapy drugs like melphalan, carmustine, or busulfan. Post-transplant care involves growth factor injections, prophylactic anti-infective medications, and platelet or blood transfusions until your counts recover. Maintenance therapies may follow to prolong remission.